Gland B2B Business Model and Growth Strategy
USA, Europe, Canada and Australia (Core Markets)
7
Revenue:
Continuing on our strategy to strengthen product portfolio,
we launched key products like Micafungin, Bivalirudin and
Ziprasidone in core markets which has helped maintain
strong growth. We have also seen strong volume based
growth for our core portfolio of products.
■ New launches:
Q4 FY21: 16 Product SKUS (10 molecules)
FY21:47 Product SKUS (28 molecules)
■ US filings update:
As of March 31, 2021, we along with our partners had 284
ANDA filings in the United States, of which 234 were
approved and 50 pending approval.
FY21: Rs. 23,610 Mn
YoY Growth: 22%
Q4 FY21: Rs. 6,193 Mn
YoY Growth: 29%
Core Markets (1)
Revenue Contribution
Q4 FY21 12M FY21
ANDA Filed
ANDA Approved
DMFS Filed
2
8(2)
21
LO
32(3)
5
FY20
FY21
61%
6%
67%
7%
USA
Europe, Canada and Australia
Note: ANDA count includes technology transfer ANDAS
(1) Core markets includes USA, Europe, Canada and Australia (2) Received first Penem approval for the US market - Ertapenem (3) Includes 5 tentative approvals
GLANDView entire presentation